- Home
- DCOY vs CLDI Comparison
DCOY vs CLDI Comparison
Compare DCOY & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCOY | CLDI |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCOY | CLDI |
|---|---|---|
| Price | $0.72 | $0.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 159.3K | 72.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $0.22 |
| 52 Week High | $1.41 | $7.32 |
Technical Indicators
Market Signals| Indicator | DCOY | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 39.00 |
| Support Level | $0.65 | $0.72 |
| Resistance Level | $0.85 | $1.58 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 13.89 | 37.34 |
Price Performance
Historical ComparisonAbout DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.